Post-translational modifications of PTEN and their potential therapeutic implications

Current Cancer Drug Targets

Volumn 11, Issue 5, 2011, Pages 536-547

  Singh, G ^a   Chan, A M ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Acetylation; Phosphatase; Phosphorylation; Post translational; PTEN; Redox; Tumor suppressor; Ubiquitination

Indexed keywords

ANTINEOPLASTIC AGENT; DJ 1 PROTEIN; ENZYME ANTIBODY; HISTONE ACETYLTRANSFERASE PCAF; NEDD4 1 PROTEIN; PDZ PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CARCINOGENESIS; COLORECTAL CANCER; DRUG CYTOTOXICITY; ENDOMETRIUM CANCER; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GLIOMA; HUMAN; INTRACELLULAR SIGNALING; NITROSYLATION; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PARKINSONISM; PDZ DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; STOMACH CANCER; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 79958155946     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911795655930     Document Type: Review

References (129)

1. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S. I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; Bigner, S. H.; Giovanella, B. C.; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M. H.; Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943-1947.
2. Li, D. M.; Sun, H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997, 57, 2124-2129.
3. Steck, P. A.; Pershouse, M. A.; Jasser, S. A.; Yung, W. K.; Lin, H.; Ligon, A. H.; Langford, L. A.; Baumgard, M. L.; Hattier, T.; Davis, T.; Frye, C.; Hu, R.; Swedlund, B.; Teng, D. H.; Tavtigian, S. V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15, 356-362.
4. Ali, I. U.; Schriml, L. M.; Dean, M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 1999, 91, 1922-1932.
5. Ueda, K.; Nishijima, M.; Inui, H.; Watatani, M.; Yayoi, E.; Okamura, J.; Yasutomi, M.; Nakamura, Y.; Miyoshi, Y. Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn. J. Cancer Res. 1998, 89, 17-21.
6. Lauge, A.; Lefebvre, C.; Laurent-Puig, P.; Caux, V.; Gad, S.; Eng, C.; Longy, M.; Stoppa-Lyonnet, D. No evidence for germline PTEN mutations in families with breast and brain tumours. Int. J. Cancer 1999, 84, 216-219.
7. FitzGerald, M. G.; Marsh, D. J.; Wahrer, D.; Bell, D.; Caron, S.; Shannon, K. E.; Ishioka, C.; Isselbacher, K. J.; Garber, J. E.; Eng, C.; Haber, D. A. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 1998, 17, 727-731.
8. Maxwell, G. L.; Risinger, J. I.; Tong, B.; Shaw, H.; Barrett, J. C.; Berchuck, A.; Futreal, P. A. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. Gynecol. Oncol. 1998, 70, 13-16.
9. Sakurada, A.; Suzuki, A.; Sato, M.; Yamakawa, H.; Orikasa, K.; Uyeno, S.; Ono, T.; Ohuchi, N.; Fujimura, S.; Horii, A. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn. J. Cancer Res. 1997, 88, 1025-1028.
10. Obata, K.; Morland, S. J.; Watson, R. H.; Hitchcock, A.; Chenevix-Trench, G.; Thomas, E. J.; Campbell, I. G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998, 58, 2095-2097.
11. Risinger, J. I.; Hayes, A. K.; Berchuck, A.; Barrett, J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997, 57, 4736-4738.
12. Maxwell, G. L.; Risinger, J. I.; Gumbs, C.; Shaw, H.; Bentley, R. C.; Barrett, J. C.; Berchuck, A.; Futreal, P. A. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998, 58, 2500-2503.
13. Risinger, J. I.; Hayes, K.; Maxwell, G. L.; Carney, M. E.; Dodge, R. K.; Barrett, J. C.; Berchuck, A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res. 1998, 4, 3005-3010.
14. Schmidt, E. E.; Ichimura, K.; Goike, H. M.; Moshref, A.; Liu, L.; Collins, V. P. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J. Neuropathol. Exp. Neurol. 1999, 58, 1170-1183.
15. Steck, P. A.; Lin, H.; Langford, L. A.; Jasser, S. A.; Koul, D.; Yung, W. K.; Pershouse, M. A. Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 1999, 24, 135-143.
16. Zhou, X. P.; Li, Y. J.; Hoang-Xuan, K.; Laurent-Puig, P.; Mokhtari, K.; Longy, M.; Sanson, M.; Delattre, J. Y.; Thomas, G.; Hamelin, R. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer 1999, 84, 150-154.
17. Wang, S. I.; Puc, J.; Li, J.; Bruce, J. N.; Cairns, P.; Sidransky, D.; Parsons, R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997, 57, 4183-4186.
18. Davies, M. P.; Gibbs, F. E.; Halliwell, N.; Joyce, K. A.; Roebuck, M. M.; Rossi, M. L.; Salisbury, J.; Sibson, D. R.; Tacconi, L.; Walker, C. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br. J. Cancer 1999, 79, 1542-1548.
19. Rasheed, B. K.; Stenzel, T. T.; McLendon, R. E.; Parsons, R.; Friedman, A. H.; Friedman, H. S.; Bigner, D. D.; Bigner, S. H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997, 57, 4187-4190.
20. Suzuki, H.; Freije, D.; Nusskern, D. R.; Okami, K.; Cairns, P.; Sidransky, D.; Isaacs, W. B.; Bova, G. S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998, 58, 204-209.
21. Vlietstra, R. J.; van Alewijk, D. C.; Hermans, K. G.; van Steenbrugge, G. J.; Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998, 58, 2720-2723.
22. Marsh, D. J.; Coulon, V.; Lunetta, K. L.; Rocca-Serra, P.; Dahia, P. L.; Zheng, Z.; Liaw, D.; Caron, S.; Duboue, B.; Lin, A. Y.; Richardson, A. L.; Bonnetblanc, J. M.; Bressieux, J. M.; Cabarrot-Moreau, A.; Chompret, A.; Demange, L.; Eeles, R. A.; Yahanda, A. M.; Fearon, E. R.; Fricker, J. P.; Gorlin, R. J.; Hodgson, S. V.; Huson, S.; Lacombe, D.; LePrat, F.; Odent, S.; Toulouse, C.; Olopade. O. I.; Sobol, H.; Tishler, S.; Woods, C. G.; Robinson, B. G.; Weber, H. C.; Parsons, R.; Peacocke, M.; Longy, M.; Eng, C. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 1998, 7, 507-515.
23. Arch, E. M.; Goodman, B. K.; Van Wesep, R. A.; Liaw, D.; Clarke, K.; Parsons, R.; McKusick, V. A.; Geraghty, M. T. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J. Med. Genet. 1997, 71, 489-493.
24. Liaw, D.; Marsh, D. J.; Li, J.; Dahia, P. L.; Wang, S. I.; Zheng, Z.; Bose, S.; Call, K. M.; Tsou, H. C.; Peacocke, M.; Eng, C.; Parsons, R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16, 64-67.
25. Gustafson, S.; Zbuk, K. M.; Scacheri, C.; Eng, C. Cowden syndrome. Semin. Oncol. 2007, 34, 428-434.
26. Maehama, T.; Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273, 13375-13378.
27. Myers, M. P.; Pass, I.; Batty, I. H.; Van der Kaay, J.; Stolarov, J. P.; Hemmings, B. A.; Wigler, M. H.; Downes, C. P.; Tonks, N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13513-13518.
28. Stambolic, V.; Suzuki, A.; de la Pompa, J. L.; Brothers, G. M.; Mirtsos, C.; Sasaki, T.; Ruland, J.; Penninger, J. M.; Siderovski, D. P.; Mak, T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95, 29-39.
29. Myers, M. P.; Stolarov, J. P.; Eng, C.; Li, J.; Wang, S. I.; Wigler, M. H.; Parsons, R.; Tonks, N. K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 9052-9057.
30. Hlobilkova, A.; Guldberg, P.; Thullberg, M.; Zeuthen, J.; Lukas, J.; Bartek, J. Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp. Cell Res. 2000, 256, 571-577.
31. Weng, L. P.; Brown, J. L.; Eng, C. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum. Mol. Genet. 2001, 10, 599-604.
32. Park, M. J.; Kim, M. S.; Park, I. C.; Kang, H. S.; Yoo, H.; Park, S. H.; Rhee, C. H.; Hong, S. I.; Lee, S. H. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res. 2002, 62, 6318-6322.
33. Gildea, J. J.; Herlevsen, M.; Harding, M. A.; Gulding, K. M.; Moskaluk, C. A.; Frierson, H. F.; Theodorescu, D. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 2004, 23, 6788-6797.
34. Davidson, L.; Maccario, H.; Perera, N. M.; Yang, X.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Weijer, C. J.; Downes, C. P.; Leslie, N. R. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene 2010, 29, 687-697.
35. Lee, J. O.; Yang, H.; Georgescu, M. M.; Di Cristofano, A.; Maehama, T.; Shi, Y.; Dixon, J. E.; Pandolfi, P.; Pavletich, N. P. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99, 323-334.
36. Rizo, J.; Sudhof, T. C. C2-domains, structure and function of a universal Ca2+-binding domain. J. Biol. Chem. 1998, 273, 15879-15882.
37. Das, S.; Dixon, J. E.; Cho, W. Membrane-binding and activation mechanism of PTEN. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 7491-7496.
38. Trotman, L. C.; Wang, X.; Alimonti, A.; Chen, Z.; Teruya-Feldstein, J.; Yang, H.; Pavletich, N. P.; Carver, B. S.; Cordon-Cardo, C.; Erdjument-Bromage, H.; Tempst, P.; Chi, S. G.; Kim, H. J.; Misteli, T.; Jiang, X.; Pandolfi, P. P. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128, 141-156.
39. Wu, X.; Hepner, K.; Castelino-Prabhu, S.; Do, D.; Kaye, M. B.; Yuan, X. J.; Wood, J.; Ross, C.; Sawyers, C. L.; Whang, Y. E. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4233-4238.
40. Bonifant, C. L.; Kim, J. S.; Waldman, T. NHERFs, NEP, MAGUKs, and more: interactions that regulate PTEN. J. Cell. Biochem. 2007, 102, 878-885.
41. Vazquez, F.; Devreotes, P. Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction. Cell Cycle 2006, 5, 1523-1527.
42. Li, A. G.; Piluso, L. G.; Cai, X.; Wei, G.; Sellers, W. R.; Liu, X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol. Cell 2006, 23, 575-587.
43. Singh, B.; Ittmann, M. M.; Krolewski, J. J. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 1998, 21, 166-171.
44. Perren, A.; Weng, L. P.; Boag, A. H.; Ziebold, U.; Thakore, K.; Dahia, P. L.; Komminoth, P.; Lees, J. A.; Mulligan, L. M.; Mutter, G. L.; Eng, C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 1999, 155, 1253-1260.
45. Adey, N. B.; Huang, L.; Ormonde, P. A.; Baumgard, M. L.; Pero, R.; Byreddy, D. V.; Tavtigian, S. V.; Bartel, P. L. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res. 2000, 60, 35-37.
46. Vazquez, F.; Ramaswamy, S.; Nakamura, N.; Sellers, W. R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 2000, 20, 5010-5018.
47. Torres, J.; Pulido, R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 2001, 276, 993-998.
48. Tolkacheva, T.; Boddapati, M.; Sanfiz, A.; Tsuchida, K.; Kimmelman, A. C.; Chan, A. M. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001, 61, 4985-4989.
49. Miller, S. J.; Lou, D. Y.; Seldin, D. C.; Lane, W. S.; Neel, B. G. Direct identification of PTEN phosphorylation sites. Federation of European Biochemical Societies 2002, 528, 145-153.
50. Al-Khouri, A. M.; Ma, Y.; Togo, S. H.; Williams, S.; Mustelin, T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J. Biol. Chem. 2005, 280, 35195-35202.
51. Maccario, H.; Perera, N. M.; Davidson, L.; Downes, C. P.; Leslie, N. R. PTEN is destabilized by phosphorylation on Thr366. Biochem. J. 2007, 405, 439-444.
52. Lu, Y.; Yu, Q.; Liu, J. H.; Zhang, J.; Wang, H.; Koul, D.; McMurray, J. S.; Fang, X.; Yung, W. K.; Siminovitch, K. A.; Mills, G. B. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 2003, 278, 40057-40066.
53. Ning, K.; Miller, L. C.; Laidlaw, H. A.; Burgess, L. A.; Perera, N. M.; Downes, C. P.; Leslie, N. R.; Ashford, M. L. A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. Embo J. 2006, 25, 2377-2387.
54. Brisbin, S.; Liu, J.; Boudreau, J.; Peng, J.; Evangelista, M.; Chin-Sang, I. A role for C. elegans Eph RTK signaling in PTEN regulation. Dev. Cell 2009, 17, 459-469.
55. Young, M. R. Tumor-derived prostaglandin E2 and transforming growth factor-beta stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidylinositide 3-kinase. Angiogenesis 2004, 7, 123-131.
56. Okahara, F.; Ikawa, H.; Kanaho, Y.; Maehama, T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J. Biol. Chem. 2004, 279, 45300-45303.
57. Kim, Y. J.; Cho, Y. E.; Kim, Y. W.; Kim, J. Y.; Lee, S.; Park, J. H. Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas. J. Pathol. 2008, 216, 218-224.
58. Nakagawa, Y.; Yoshida, A.; Numoto, K.; Kunisada, T.; Wai, D.; Ohata, N.; Takeda, K.; Kawai, A.; Ozaki, T. Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization. Oncol. Rep. 2006, 15, 297-303.
59. Merritt, M. A.; Parsons, P. G.; Newton, T. R.; Martyn, A. C.; Webb, P. M.; Green, A. C.; Papadimos, D. J.; Boyle, G. M. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer 2009, 9, 378.
60. Yim, J. H.; Kim, Y. J.; Cho, Y. E.; Ko, J. H.; Kim, S. M.; Kim, J. Y.; Park, J. H. GLTSCR2 sensitizes cells to hypoxic injury without involvement of mitochondrial apoptotic cascades. Pathobiology 2007, 74, 301-308.
61. Ji, D.; Deeds, S. L.; Weinstein, E. J. A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol. Rep. 2007, 18, 1499-1505.
62. Omori, N.; Jin, G.; Li, F.; Zhang, W. R.; Wang, S. J.; Hamakawa, Y.; Nagano, I.; Manabe, Y.; Shoji, M.; Abe, K. Enhanced phosphorylation of PTEN in rat brain after transient middle cerebral artery occlusion. Brain Res. 2002, 954, 317-322.
63. Cheong, J. W.; Eom, J. I.; Maeng, H. Y.; Lee, S. T.; Hahn, J. S.; Ko, Y. W.; Min, Y. H. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br. J. Haematol. 2003, 122, 454-456.
64. Odriozola, L.; Singh, G.; Hoang, T.; Chan, A. M. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J. Biol. Chem. 2007, 282, 23306-23315.
65. Vazquez, F.; Grossman, S. R.; Takahashi, Y.; Rokas, M. V.; Nakamura, N.; Sellers, W. R. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 2001, 276, 48627-48630.
66. Torres, J.; Rodriguez, J.; Myers, M. P.; Valiente, M.; Graves, J. D.; Tonks, N. K.; Pulido, R. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J. Biol. Chem. 2003, 278, 30652-30660.
67. Rahdar, M.; Inoue, T.; Meyer, T.; Zhang, J.; Vazquez, F.; Devreotes, P. N. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 480-485.
68. Xu, D.; Yao, Y.; Jiang, X.; Lu, L.; Dai, W. Regulation of PTEN Stability and Activity by Plk3. J. Biol. Chem. 2010, 285, 39935-39942.
69. Xie, S.; Wu, H.; Wang, Q.; Kunicki, J.; Thomas, R. O.; Hollingsworth, R. E.; Cogswell, J.; Dai, W. Genotoxic stressinduced activation of Plk3 is partly mediated by Chk2. Cell Cycle 2002, 1, 424-429.
70. Xie, S.; Wu, H.; Wang, Q.; Cogswell, J. P.; Husain, I.; Conn, C.; Stambrook, P.; Jhanwar-Uniyal, M.; Dai, W. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J. Biol. Chem. 2001, 276, 43305-43312.
71. Yang, Y.; Bai, J.; Shen, R.; Brown, S. A.; Komissarova, E.; Huang, Y.; Jiang, N.; Alberts, G. F.; Costa, M.; Lu, L.; Winkles, J. A.; Dai, W. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res. 2008, 68, 4077-4085.
72. Wang, L.; Gao, J.; Dai, W.; Lu, L. Activation of Polo-like kinase 3 by hypoxic stresses. J. Biol. Chem. 2008, 283, 25928-25935.
73. Takai, N.; Hamanaka, R.; Yoshimatsu, J.; Miyakawa, I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24, 287-291.
74. Shabek, N.; Ciechanover, A. Degradation of ubiquitin: the fate of the cellular reaper. Cell Cycle 2010, 9, 523-530.
75. Wu, W.; Wang, X.; Zhang, W.; Reed, W.; Samet, J. M.; Whang, Y. E.; Ghio, A. J. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J. Biol. Chem. 2003, 278, 28258-28263.
76. Duerr, E. M.; Rollbrocker, B.; Hayashi, Y.; Peters, N.; Meyer-Puttlitz, B.; Louis, D. N.; Schramm, J.; Wiestler, O. D.; Parsons, R.; Eng, C.; von Deimling, A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16, 2259-2264.
77. Fouladkou, F.; Landry, T.; Kawabe, H.; Neeb, A.; Lu, C.; Brose, N.; Stambolic, V.; Rotin, D. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 8585-8590.
78. Yim, E. K.; Peng, G.; Dai, H.; Hu, R.; Li, K.; Lu, Y.; Mills, G. B.; Meric-Bernstam, F.; Hennessy, B. T.; Craven, R. J.; Lin, S. Y. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15, 304-314.
79. Kwak, Y. D.; Wang, B.; Pan, W.; Xu, H.; Jiang, X.; Liao, F. F. Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc. J. Biol. Chem. 2010, 285, 9847-9857.
80. Mund, T.; Pelham, H. R. Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2. Proc. Natl. Acad. Sci. U.S.A 2010, 107, 11429-11434.
81. Oliver, P. M.; Cao, X.; Worthen, G. S.; Shi, P.; Briones, N.; MacLeod, M.; White, J.; Kirby, P.; Kappler, J.; Marrack, P.; Yang, B. Ndfip1 protein promotes the function of itch ubiquitin ligase to prevent T cell activation and T helper 2 cell-mediated inflammation. Immunity 2006, 25, 929-940.
82. Foot, N. J.; Dalton, H. E.; Shearwin-Whyatt, L. M.; Dorstyn, L.; Tan, S. S.; Yang, B.; Kumar, S. Regulation of the divalent metal ion transporter DMT1 and iron homeostasis by a ubiquitindependent mechanism involving Ndfips and WWP2. Blood 2008, 112, 4268-4275.
83. Hettema, E. H.; Valdez-Taubas, J.; Pelham, H. R. Bsd2 binds the ubiquitin ligase Rsp5 and mediates the ubiquitination of transmembrane proteins. EMBO J. 2004, 23, 1279-1288.
84. Howitt, J.; Putz, U.; Lackovic, J.; Doan, A.; Dorstyn, L.; Cheng, H.; Yang, B.; Chan-Ling, T.; Silke, J.; Kumar, S.; Tan, S. S. Divalent metal transporter 1 (DMT1) regulation by Ndfip1 prevents metal toxicity in human neurons. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 15489-15494.
85. Galban, S.; Duckett, C. S. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ. 2010, 17, 54-60.
86. Downward, J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 2004, 15, 177-182.
87. Van Themsche, C.; Leblanc, V.; Parent, S.; Asselin, E. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J. Biol. Chem. 2009, 284, 20462-20466.
88. Maccario, H.; Perera, N. M.; Gray, A.; Downes, C. P.; Leslie, N. R. Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J. Biol. Chem. 2010, 285, 12620-12628.
89. Muratani, M.; Gerlich, D.; Janicki, S. M.; Gebhard, M.; Eils, R.; Spector, D. L. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat. Cell Biol. 2002, 4, 106-110.
90. Song, M. S.; Salmena, L.; Carracedo, A.; Egia, A.; Lo-Coco, F.; Teruya-Feldstein, J.; Pandolfi, P. P. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008, 455, 813-817.
91. Leslie, N. R. The redox regulation of PI 3-kinase-dependent signaling. Antioxid. Redox Signal. 2006, 8, 1765-1774.
92. Leslie, N. R.; Bennett, D.; Lindsay, Y. E.; Stewart, H.; Gray, A.; Downes, C. P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003, 22, 5501-5510.
93. Lee, S. R.; Yang, K. S.; Kwon, J.; Lee, C.; Jeong, W.; Rhee, S. G. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 2002, 277, 20336-20342.
94. Cao, J.; Schulte, J.; Knight, A.; Leslie, N. R.; Zagozdzon, A.; Bronson, R.; Manevich, Y.; Beeson, C.; Neumann, C. A. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 2009, 28, 1505-1517.
95. Hui, S. T.; Andres, A. M.; Miller, A. K.; Spann, N. J.; Potter, D. W.; Post, N. M.; Chen, A. Z.; Sachithanantham, S.; Jung, D. Y.; Kim, J. K.; Davis, R. A. Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3921-3926.
96. Pelicano, H.; Xu, R. H.; Du, M.; Feng, L.; Sasaki, R.; Carew, J. S.; Hu, Y.; Ramdas, L.; Hu, L.; Keating, M. J.; Zhang, W.; Plunkett, W.; Huang, P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J. Cell Biol. 2006, 175, 913-923.
97. Kwon, J.; Qu, C. K.; Maeng, J. S.; Falahati, R.; Lee, C.; Williams, M. S. Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76-ADAP. EMBO J. 2005, 24, 2331-2341.
98. Seo, J. H.; Ahn, Y.; Lee, S. R.; Yeol Yeo, C.; Chung Hur, K. The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol. Biol. Cell 2005, 16, 348-357.
99. Chang, C. J.; Mulholland, D. J.; Valamehr, B.; Mosessian, S.; Sellers, W. R.; Wu, H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol. Cell. Biol. 2008, 28, 3281-3289.
100. Pei, D. S.; Sun, Y. F.; Song, Y. J. S-nitrosylation of PTEN Invovled in ischemic brain injury in rat hippocampal CA1 region. Neurochem. Res. 2009, 34, 1507-1512.
101. Kwak, Y. D.; Ma, T.; Diao, S.; Zhang, X.; Chen, Y.; Hsu, J.; Lipton, S. A.; Masliah, E.; Xu, H.; Liao, F. F. NO signaling and Snitrosylation regulate PTEN inhibition in neurodegeneration. Mol. Neurodegener. 2010, 5, 49.
102. Lee, S. J.; Kim, S. J.; Kim, I. K.; Ko, J.; Jeong, C. S.; Kim, G. H.; Park, C.; Kang, S. O.; Suh, P. G.; Lee, H. S.; Cha, S. S. Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. J. Biol. Chem. 2003, 278, 44552-44559.
103. Honbou, K.; Suzuki, N. N.; Horiuchi, M.; Niki, T.; Taira, T.; Ariga, H.; Inagaki, F. The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J. Biol. Chem. 2003, 278, 31380-31384.
104. Nagakubo, D.; Taira, T.; Kitaura, H.; Ikeda, M.; Tamai, K.; Iguchi-Ariga, S. M.; Ariga, H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 1997, 231, 509-513.
105. Bonifati, V.; Rizzu, P.; van Baren, M. J.; Schaap, O.; Breedveld, G. J.; Krieger, E.; Dekker, M. C.; Squitieri, F.; Ibanez, P.; Joosse, M.; van Dongen, J. W.; Vanacore, N.; van Swieten, J. C.; Brice, A.; Meco, G.; van Duijn, C. M.; Oostra, B. A.; Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299, 256-259.
106. Hod, Y.; Pentyala, S. N.; Whyard, T. C.; El-Maghrabi, M. R. Identification and characterization of a novel protein that regulates RNA-protein interaction. J. Cell. Biochem. 1999, 72, 435-444.
107. Okada, M.; Matsumoto, K.; Niki, T.; Taira, T.; Iguchi-Ariga, S. M.; Ariga, H. DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice. Biol. Pharm. Bull. 2002, 25, 853-856.
108. Niki, T.; Takahashi-Niki, K.; Taira, T.; Iguchi-Ariga, S. M.; Ariga, H. DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Mol. Cancer Res. 2003, 1, 247-261.
109. Canet-Aviles, R. M.; Wilson, M. A.; Miller, D. W.; Ahmad, R.; McLendon, C.; Bandyopadhyay, S.; Baptista, M. J.; Ringe, D.; Petsko, G. A.; Cookson, M. R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 9103-9108.
110. Kim, R. H.; Peters, M.; Jang, Y.; Shi, W.; Pintilie, M.; Fletcher, G. C.; DeLuca, C.; Liepa, J.; Zhou, L.; Snow, B.; Binari, R. C.; Manoukian, A. S.; Bray, M. R.; Liu, F. F.; Tsao, M. S.; Mak, T. W. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005, 7, 263-273.
111. Kim, Y. C.; Kitaura, H.; Taira, T.; Iguchi-Ariga, S. M.; Ariga, H. Oxidation of DJ-1-dependent cell transformation through direct binding of DJ-1 to PTEN. Int. J. Oncol. 2009, 35, 1331-1341.
112. Davidson, B.; Hadar, R.; Schlossberg, A.; Sternlicht, T.; Slipicevic, A.; Skrede, M.; Risberg, B.; Florenes, V. A.; Kopolovic, J.; Reich, R. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum. Pathol. 2008, 39, 87-95.
113. Zhou, C.; Huang, Y.; Przedborski, S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N.Y. Acad. Sci. 2008, 1147, 93-104.
114. Miller, D. W.; Ahmad, R.; Hague, S.; Baptista, M. J.; Canet-Aviles, R.; McLendon, C.; Carter, D. M.; Zhu, P. P.; Stadler, J.; Chandran, J.; Klinefelter, G. R.; Blackstone, C.; Cookson, M. R. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem. 2003, 278, 36588-36595.
115. van der Brug, M. P.; Blackinton, J.; Chandran, J.; Hao, L. Y.; Lal, A.; Mazan-Mamczarz, K.; Martindale, J.; Xie, C.; Ahmad, R.; Thomas, K. J.; Beilina, A.; Gibbs, J. R.; Ding, J.; Myers, A. J.; Zhan, M.; Cai, H.; Bonini, N. M.; Gorospe, M.; Cookson, M. R. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 10244-10249.
116. Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 2000, 19, 1176-1179.
117. Brownell, J. E.; Zhou, J.; Ranalli, T.; Kobayashi, R.; Edmondson, D. G.; Roth, S. Y.; Allis, C. D. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996, 84, 843-851.
118. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363, 15-23.
119. Gu, W.; Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90, 595-606.
120. Okumura, K.; Mendoza, M.; Bachoo, R. M.; DePinho, R. A.; Cavenee, W. K.; Furnari, F. B. PCAF modulates PTEN activity. J. Biol. Chem. 2006, 281, 26562-26568.
121. Kim, J. W.; Kang, K. H.; Burrola, P.; Mak, T. W.; Lemke, G. Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium. Genes Dev. 2008, 22, 3147-3157.
122. Ikenoue, T.; Inoki, K.; Zhao, B.; Guan, K. L. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008, 68, 6908-6912.
123. You, Y.; Geng, X.; Zhao, P.; Fu, Z.; Wang, C.; Chao, S.; Liu, N.; Lu, A.; Gardner, K.; Pu, P.; Kong, C.; Ge, Y.; Judge, S. I.; Li, Q. Q. Evaluation of combination gene therapy with PTEN and antisense hTERT for malignant glioma in vitro and xenografts. Cell Mol. Life Sci. 2007, 64, 621-631.
124. Hang, Y.; Zheng, Y. C.; Cao, Y.; Li, Q. S.; Sui, Y. J. Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene. World J. Gastroenterol. 2005, 11, 2224-2229.
125. Saito, Y.; Swanson, X.; Mhashilkar, A. M.; Oida, Y.; Schrock, R.; Branch, C. D.; Chada, S.; Zumstein, L.; Ramesh, R. Adenovirusmediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther. 2003, 10, 1961-1969.
126. Tanaka, M.; Grossman, H. B. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther. 2003, 10, 1636-1642.
127. Sakurada, A.; Hamada, H.; Fukushige, S.; Yokoyama, T.; Yoshinaga, K.; Furukawa, T.; Sato, S.; Yajima, A.; Sato, M.; Fujimura, S.; Horii, A. Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int. J. Oncol. 1999, 15, 1069-1074.
128. Hacein-Bey-Abina, S.; Garrigue, A.; Wang, G. P.; Soulier, J.; Lim, A.; Morillon, E.; Clappier, E.; Caccavelli, L.; Delabesse, E.; Beldjord, K.; Asnafi, V.; MacIntyre, E.; Dal Cortivo, L.; Radford, I.; Brousse, N.; Sigaux, F.; Moshous, D.; Hauer, J.; Borkhardt, A.; Belohradsky, B. H.; Wintergerst, U.; Velez, M. C.; Leiva, L.; Sorensen, R.; Wulffraat, N.; Blanche, S.; Bushman, F. D.; Fischer, A.; Cavazzana-Calvo, M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118, 3132-3142.
129. Zhu, D.; Hensel, J.; Hilgraf, R.; Abbasian, M.; Pornillos, O.; Deyanat-Yazdi, G.; Hua, X. H.; Cox, S. Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth. Mol. Cell. Biochem. 2010, 333, 159-167.